medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 4

<< Back Next >>

Med Int Mex 2007; 23 (4)

Ezetimiba plus statins effects over lipids in Mexican patients

Carranza MJ, Herrera CA, Lemus CH

Language: Spanish
References: 21
Page: 280-285
PDF size: 219.92 Kb.


ABSTRACT

Background: The percentage of patients treated with statins who reach the low-density lipoproteins cholesterol goal is low.
Objective: This trial was designed to determine the effects of ezetimiba plus statins on lipid profile from Mexican patients with LDL-C values above the goal.
Methods: Forty eight patients with LDL-C levels above the goal established by the National Cholesterol Education Program, Adult Treatment Panel III were included in an observational, prospective, open, and blinded for laboratory technicians trial in which total cholesterol, triglycerides and high-density lipoprotein cholesterol were measured, and LDL-C values were estimated by means of Friedewald’s formula. Evaluations were made in a certified laboratory by the American College of Pathologists at the start of the trial and eight weeks after treatment with ezetimibe 10 mg plus statins.
Results: The LDL-C goal was reached by 83.3%. There were significantly decrements in total cholesterol by 37%, LDL-C by 51% and triglycerids by 18%. Against previously reported HDL-C levels were significantly reduced by 6.8%. This decrement was observed in all groups of patients but male, subjects with hypoalphalipoproteinemia, and those treated with rosuvastatin plus ezetimibe.
Conclusions: Ezetimibe plus statins produced remarkable decrements on LDL-C, on triglycerids led to less intensive but significant reductions. However on HDL-C there were important decrements whose potential repercussions are unknown.


REFERENCES

  1. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.

  2. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001;357:577-81.

  3. Sever PS, Dahlof B, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

  4. Durrington PN. Dyslipidaemia. Lancet 2003;362:717-31.

  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.

  6. Grundy SM, Cleeman JI, Merz CN, Brewer HB, et al. Implications of recent clinical trials for the National Cholesterol Education Program, Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.

  7. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assesment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.

  8. Foley KA, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92:79-81.

  9. Alpizar M. National survey to determine the percentage of patients who reach the goals stablished by National Cholesterol Education Program (NCEP) when they are managed with statins. Diabetes 2005;54(Suppl 1):A590.

  10. Bays H, Drehobl M, Rosenblatt S, Toth P, et al. Low-density lipoprotein cholesterol reduction by SCH-58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: results of a dose-response study. Atherosclerosis 2000;151:135.

  11. Kosoglu T, Meyer I, Musiol B. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000;151:135.

  12. Kerzner B, Corbelli J, Sharp S, Lipka LJ, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24.

  13. Davidson MH, McGarry T, Bettis R. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34.

  14. Ballantyne CN, Houri J, Notarbartolo A, for the Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. A prospective, randomized, double-blind trial. Circulation 2003;107:2409-15.

  15. Gagné C, Bays HE, Weiss SR, Mata P, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91.

  16. Mackness MI, Durrington PN. High-density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.

  17. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, et al. For the DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107:1733-37.

  18. Sniderman EA. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90:48-54.

  19. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.

  20. De Jongh S, Lilien MR, Roodt J, Stroes ES, et al. Early statin therapy restores endotelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-21.

  21. Garcia E, Carranza J, Alvarez C. Effects of bezafibrate + simvastatin and bezafibrate + ezetimibe on lipid profile and flowdependent vasodilation in hypertensive patients with hypertriglyceridemia and low HDL-cholesterol levels. Proceedings of the XVIth Scientific Meeting of the Interamerican Society of Hypertension, Cancun, Q. Roo, Mexico, april 2005:148.




2020     |     www.medigraphic.com